These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 25079039)

  • 21. The use of insulin in elderly patients with type 2 diabetes mellitus.
    Mannucci E; Cremasco F; Romoli E; Rossi A
    Expert Opin Pharmacother; 2011 Dec; 12(18):2865-81. PubMed ID: 22087577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
    Massi-Benedetti M; Orsini-Federici M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exendin-4 treatment of nonobese diabetic mice increases beta-cell proliferation and fractional insulin reactive area.
    Xue S; Wasserfall C; Parker M; McGrail S; McGrail K; Campbell-Thompson M; Schatz DA; Atkinson MA; Haller MJ
    J Diabetes Complications; 2010; 24(3):163-7. PubMed ID: 19217320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials.
    Min T; Bain SC
    Expert Opin Emerg Drugs; 2023 Mar; 28(1):1-15. PubMed ID: 36896700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iatrogenic hyperinsulinemia in type 1 diabetes: its effect on atherogenic risk markers.
    Wang MY; Yu X; Lee Y; McCorkle SK; Clark GO; Strowig S; Unger RH; Raskin P
    J Diabetes Complications; 2013; 27(1):70-4. PubMed ID: 23079124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emergence of promising therapies in diabetes mellitus.
    Akkati S; Sam KG; Tungha G
    J Clin Pharmacol; 2011 Jun; 51(6):796-804. PubMed ID: 20705952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-1 antagonists for diabetes.
    Mandrup-Poulsen T;
    Expert Opin Investig Drugs; 2013 Aug; 22(8):965-79. PubMed ID: 23705588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel therapies in the management of type I diabetes mellitus.
    Ludvigsson J
    Panminerva Med; 2012 Dec; 54(4):257-70. PubMed ID: 23123577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained IL-1alpha, IL-4, and IL-6 elevations following correction of hyperglycemia in children with type 1 diabetes mellitus.
    Rosa JS; Flores RL; Oliver SR; Pontello AM; Zaldivar FP; Galassetti PR
    Pediatr Diabetes; 2008 Feb; 9(1):9-16. PubMed ID: 18211631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. At last, a weight neutral insulin?
    Fritsche A; Häring H
    Int J Obes Relat Metab Disord; 2004 Sep; 28 Suppl 2():S41-6. PubMed ID: 15306837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine.
    Ulrich H; Snyder B; Garg SK
    Vasc Health Risk Manag; 2007; 3(3):245-54. PubMed ID: 17703632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: the role of insulin analogs.
    Rossetti P; Porcellati F; Bolli GB; Fanelli CG
    Diabetes Care; 2008 Feb; 31 Suppl 2():S113-20. PubMed ID: 18227470
    [No Abstract]   [Full Text] [Related]  

  • 33. The efficacy of Prosopis glandulosa as antidiabetic treatment in rat models of diabetes and insulin resistance.
    George C; Lochner A; Huisamen B
    J Ethnopharmacol; 2011 Sep; 137(1):298-304. PubMed ID: 21645608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of two patients with generalized pustular psoriasis with the interleukin-1β inhibitor gevokizumab.
    Mansouri B; Richards L; Menter A
    Br J Dermatol; 2015 Jul; 173(1):239-41. PubMed ID: 25495649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases.
    Owyang AM; Issafras H; Corbin J; Ahluwalia K; Larsen P; Pongo E; Handa M; Horwitz AH; Roell MK; Haak-Frendscho M; Masat L
    MAbs; 2011; 3(1):49-60. PubMed ID: 21048425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset.
    Cabrera SM; Wang X; Chen YG; Jia S; Kaldunski ML; Greenbaum CJ; ; Mandrup-Poulsen T; ; Hessner MJ
    Eur J Immunol; 2016 Apr; 46(4):1030-46. PubMed ID: 26692253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin gene therapy for type 1 diabetes mellitus.
    Handorf AM; Sollinger HW; Alam T
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():37-45. PubMed ID: 25894126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 100 YEARS OF INSULIN: Arresting or curing type 1 diabetes: an elusive goal, but closing the gap.
    Martens PJ; Gysemans C; Mathieu C
    J Endocrinol; 2021 May; 249(2):T1-T11. PubMed ID: 33729180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-1 antagonism in type 1 diabetes of long duration.
    Seelig E; Timper K; Falconnier C; Stoeckli R; Bilz S; Oram R; McDonald TJ; Donath MY
    Diabetes Metab; 2016 Dec; 42(6):453-456. PubMed ID: 27720360
    [No Abstract]   [Full Text] [Related]  

  • 40. Phytochemicals as modulators of β-cells and immunity for the therapy of type 1 diabetes: Recent discoveries in pharmacological mechanisms and clinical potential.
    Apaya MK; Kuo TF; Yang MT; Yang G; Hsiao CL; Chang SB; Lin Y; Yang WC
    Pharmacol Res; 2020 Jun; 156():104754. PubMed ID: 32173584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.